Sagimet Biosciences SGMT Income Statement (2022-2026)

NASDAQ SGMT
$10.72 -0.20 (-1.83%)
As of: Sep 4, 2026 · 11:49 AM EDT
Reported Financials

Sagimet Biosciences Quarterly Income Statement

Periods 17 quarters
Latest Jun 2026

Sagimet Biosciences reported net income of -$14.04M for the quarter ended Jun 2026. This income statement covers 17 quarters of results from Jun 2022 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Income Statement Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Shares Outstanding (Entity)Shares Outstanding (Entity.) 0.19M0.19M0.19M0.19M0.21M22.90M22.90M29.04M31.91M32.14M31.35M32.20M32.20M32.46M32.35M32.56M53.11M
Revenue & cost
Revenue 2.00M
Operating items
Research & DevelopmentR&D 6.37M6.84M5.85M4.49M4.68M4.96M5.66M5.26M6.31M12.65M14.22M15.34M7.25M9.73M6.73M7.00M11.54M
Wages, Salaries and OtherWages 1.48M1.52M1.71M1.82M1.95M1.77M1.73M1.69M2.17M2.09M
Selling, General & AdministrativeSG&A 0.87M0.85M1.54M2.28M2.38M4.49M3.81M3.51M4.28M4.25M3.98M4.52M4.68M4.60M4.03M4.72M4.28M
Operating ExpensesOpex 7.24M7.69M7.39M6.76M7.06M9.45M9.47M8.77M10.59M16.90M18.20M19.86M11.93M14.33M10.77M11.71M15.82M
Operating IncomeOp. Inc -7.24M-7.69M-7.39M-6.76M-7.06M-7.45M-9.47M-8.77M-10.59M-16.90M-18.20M-19.86M-11.93M-14.33M-10.77M-11.71M-15.82M
EBIT -7.24M-7.69M-7.39M-6.76M-7.06M-7.45M-9.47M-8.77M-10.59M-16.90M-18.20M-19.86M-11.93M-14.33M-10.77M-11.71M-15.82M
Non-operating items
Interest & Investment IncomeInt & Inv Inc -0.11M0.22M0.19M0.07M0.01M1.09M1.31M-0.02M-0.03M2.28M1.99M-0.11M1.54M1.43M1.20M-0.11M1.86M
Other Non Operating IncomeOther Non Op Inc. 0.14M0.22M0.19M0.18M0.27M1.10M1.31M2.14M2.47M2.28M1.99M1.69M1.54M1.43M1.20M1.06M1.86M
Net income details
EBT -7.34M-7.47M-7.20M-6.69M-7.04M-6.36M-8.15M-8.79M-10.62M-14.62M-16.20M-19.97M-10.39M-12.91M-9.57M-11.82M-13.95M
Profit After TaxPAT -7.10M-7.52M-7.12M-6.59M-6.79M-6.35M-8.15M-6.63M-8.12M-14.62M-16.20M-18.18M-10.43M-12.91M-9.56M-10.65M-14.04M
Income from Continuing OperationsIncome (Continuing) -7.34M-7.47M-7.20M-6.69M-7.04M-6.36M-8.15M-8.79M-10.62M-14.62M-16.20M-19.97M-10.39M-12.91M-9.57M-11.82M-13.95M
Consolidated Net IncomeConsol Net Inc. -7.34M-7.47M-7.20M-6.69M-7.04M-6.36M-8.15M-8.79M-10.62M-14.62M-16.20M-19.97M-10.39M-12.91M-9.57M-11.82M-13.95M
Income towards Parent CompanyParent Net Inc -7.34M-7.47M-7.20M-6.69M-7.04M-6.36M-8.15M-8.79M-10.62M-14.62M-16.20M-19.97M-10.39M-12.91M-9.57M-11.82M-13.95M
Net Income towards Common StockholdersNet Income -7.34M-7.47M-7.20M-6.69M-7.04M-6.36M-8.15M-8.79M-10.62M-14.62M-16.20M-19.97M-10.39M-12.91M-9.57M-11.82M-13.95M
Additional items
EPS (Basic) -39.68-40.35-38.97-36.16-37.17-0.35-0.78-0.30-0.33-0.45-0.52-0.62-0.32-0.40-0.30-0.36-0.26
EPS (Diluted) -39.68-40.35-38.97-36.16-37.17-0.35-0.78-0.30-0.33-0.45-0.52-0.62-0.32-0.40-0.30-0.36-0.26
Shares Outstanding 0.19M0.19M0.18M0.19M0.19M18.19M10.46M29.04M31.91M32.14M31.35M32.20M32.20M32.46M32.35M32.56M53.11M
Shares Outstanding (Diluted)Shares Outstanding (Dil.) 0.19M0.19M0.18M0.19M0.19M18.19M10.46M29.04M31.91M32.14M31.35M32.20M32.20M32.46M32.35M32.56M53.11M
EBITDA -7.24M-7.69M-7.39M-6.76M-7.06M-7.45M-9.47M-8.77M-10.59M-16.90M-18.20M-19.86M-11.93M-14.33M-10.77M-11.71M-15.82M